Name | Bcl-2-IN-9 |
---|
Description | Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells[1]. |
---|---|
Related Catalog | |
Target |
Bcl-2:2.9 μM (IC50, [1]) |
In Vitro | Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) inhibits HL-60 cells in vitro[1]. Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) shows low cytotoxic effects against WI-38 cells with cell viability of 91%[1]. Bcl-2-IN-9 (compound 6e) (10 μM, 48 hours) displays a high selectivity against leukemia cells[1]. Bcl-2-IN-9 (compound 6e) (10 μM) mediates apoptotic by down-regulating expression of Bcl-2 and causing chromatin compaction and nuclear fragmentation[1]. Cell Viability Assay[1] Cell Line: HL-60 cells Concentration: 1, 10, 20, 40 μM Incubation Time: 48 hours Result: Surpressed cell growth and viability to 28.9%. Cell Cytotoxicity Assay[1] Cell Line: WT-38 cells Concentration: 10 μM Incubation Time: 48 hours Result: Low cytotoxic effects. Apoptosis Analysis[1] Cell Line: HL-60 cells Concentration: 1, 10, 20, 40 μM Incubation Time: 48 hours Result: Caused chromatin compaction and nuclear fragmentation. |
References |
Molecular Formula | C27H31N7O3S |
---|---|
Molecular Weight | 533.65 |